HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
122,458,776
Share change
-3,143,595
Total reported value
$5,856,815,335
Put/Call ratio
39%
Price per share
$47.81
Number of holders
500
Value change
-$193,231,691
Number of buys
238
Number of sells
257

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2024

As of 31 Dec 2024, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 500 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 122,458,776 shares. The largest 10 holders included BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, BANK OF AMERICA CORP /DE/, ALLIANCEBERNSTEIN L.P., GEODE CAPITAL MANAGEMENT, LLC, MACQUARIE GROUP LTD, JPMORGAN CHASE & CO, and Invesco Ltd.. This page lists 501 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.